Docket No.: P51359

## 20/516836 Rec'd PEOPTO 03 DEC 2004 DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

"NF-KB INHIBITORS"					
the spe [ ] [X]	is attached here	<b>29 May 2003</b> as Seria		<b>7385</b> blicable).	
I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.					
		y to disclose information ations, Section 1.56.	on which is material t	to the patentability as defined in Ti	itle 37,
I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.					
Prior F Numbe	oreign Applicat	ion(s) Country	Filing Date	Priority Claimed	
Applica 60/386	ation(s) listed be ation Number 5,556	Filing Date 6 June 2002	-	tion 119(e) of any United States protein 120 of any United States and	
Section the sub Interna 112, I Code of	n 365(c) of any lapted piect matter of eational application acknowledge the federal Regul	PCT International applach of the claims of thi on in the manner provide duty to disclose infor	ication designating the sapplication is not did to the first paragemation which is mate thich became available	tion 120 of any United States applied United States, listed below and, isclosed in the prior United States raph of Title 35, United States Corrial to patentability as defined in The between the filing date of the prior application.	insofar as or PCT de, Section Fitle 37,
Serial 1	No.	Filing Date	Status		

Address all correspondence and telephone calls to Customer Number 20462 Laura K. Madden, GlaxoSmithKline, CIP-U.S., UW2220, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, whose telephone number is 610-270-7339.

I hereby appoint the practitioners associated with the Customer Numbers provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith Customer Number 20462 and Customer Number 23347.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon

Full Name of Inventor:

James F. CALLAHAN

Inventor's Signature:

Date: 13 - 747e - 2003

Residence:

King of Prussia, Pennsylvania 19406

Citizenship:

United States of America

Post Office Address: GlaxoSmithKline

Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Yue Hu

Inventor's Signature:

Residence:

King of Prussia, Pennsylvania 19406

Citizenship:

China

Post Office Address: GlaxoSmithKline

Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, Pennsylvania 19406-0939